Pemigatinib Patent Expiration
Pemigatinib is used for treating cholangiocarcinoma and myeloid/lymphoid neoplasms with specific genetic rearrangements in patients who have not responded to previous treatments. It was first introduced by Incyte Corp
Pemigatinib Patents
Given below is the list of patents protecting Pemigatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pemazyre | US12552792 | Solid Forms Of An Fgfr Inhibitor And Processes For Preparing The Same | Oct 03, 2040 | Incyte Corp |
| Pemazyre | US11628162 | Methods of treating cancer with an FGFR inhibitor | Aug 30, 2040 | Incyte Corp |
| Pemazyre | US11466004 | Solid forms of an FGFR inhibitor and processes for preparing the same | May 03, 2039 | Incyte Corp |
| Pemazyre | US9611267 | Substituted tricyclic compounds as FGFR inhibitors | Jan 30, 2035 | Incyte Corp |
| Pemazyre | US10131667 | Substituted tricyclic compounds as FGFR inhibitors | Apr 17, 2034 | Incyte Corp |
Pemigatinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pemigatinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
